Modeling the economic benefits of an AIDS vaccine

David Bishai; Maria K. Lin; C. W.B. Kiyonga

doi:10.1016/S0264-410X(01)00335-8

Modeling the economic benefits of an AIDS vaccine

David Bishai, Maria K. Lin, C. W.B. Kiyonga

School of Medicine

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Economic models were used to describe the potential for an AIDS vaccine to prevent medical spending and lost productivity throughout the world. In terms of avoided medical spending, preventing 75% of the AIDS risk for 10 years in one adult male is estimated to be worth US$ 343 in western Europe, US$ 4.59 in south and SE Asia, and US$ 2.67 in sub-Saharan Africa. The expected medical savings from a 75% effective vaccine would exceed US$ 25.00 per person for over 700 million people. Although an AIDS vaccine would save more lives in poverty stricken areas, it would save more money in developed countries. The mismatch between the public health needs and market forces is highlighted by this model.

Original language	English (US)
Pages (from-to)	526-531
Number of pages	6
Journal	Vaccine
Volume	20
Issue number	3-4
DOIs	https://doi.org/10.1016/S0264-410X(01)00335-8
State	Published - Nov 12 2001

Keywords

AIDS
Costs
Demand
Economics
Epidemiology
HIV
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/S0264-410X(01)00335-8

Cite this

@article{12c98ad68a2a4ba6a14eb96ac609cf6e,

title = "Modeling the economic benefits of an AIDS vaccine",

abstract = "Economic models were used to describe the potential for an AIDS vaccine to prevent medical spending and lost productivity throughout the world. In terms of avoided medical spending, preventing 75% of the AIDS risk for 10 years in one adult male is estimated to be worth US$ 343 in western Europe, US$ 4.59 in south and SE Asia, and US$ 2.67 in sub-Saharan Africa. The expected medical savings from a 75% effective vaccine would exceed US$ 25.00 per person for over 700 million people. Although an AIDS vaccine would save more lives in poverty stricken areas, it would save more money in developed countries. The mismatch between the public health needs and market forces is highlighted by this model.",

keywords = "AIDS, Costs, Demand, Economics, Epidemiology, HIV, Vaccine",

author = "David Bishai and Lin, {Maria K.} and Kiyonga, {C. W.B.}",

note = "Funding Information: The authors gratefully acknowledge the suggestions of seminar participants at the World Bank, The Welch Center, and The International Health Economics Association, and UNAIDS. Special thanks are due to Martha Ainsworth, Amie Batson, Stefano Bertozzi, Don Burke, Jos{\'e} Esparza, Mark Kane, Bob Lawrence, Richard Mahoney, Philip Musgrove, Ken Nelson, and Tomas Philipson. All errors are our own. Grant support: World Bank (DB, MKL), the Hopkins Population Center, NIH Grant SP30HD06268-25(DB), and the Bill and Melinda Gates Institute for Population and Reproductive Health (CWBK).",

year = "2001",

month = nov,

day = "12",

doi = "10.1016/S0264-410X(01)00335-8",

language = "English (US)",

volume = "20",

pages = "526--531",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "3-4",

}

TY - JOUR

T1 - Modeling the economic benefits of an AIDS vaccine

AU - Bishai, David

AU - Lin, Maria K.

AU - Kiyonga, C. W.B.

N1 - Funding Information: The authors gratefully acknowledge the suggestions of seminar participants at the World Bank, The Welch Center, and The International Health Economics Association, and UNAIDS. Special thanks are due to Martha Ainsworth, Amie Batson, Stefano Bertozzi, Don Burke, José Esparza, Mark Kane, Bob Lawrence, Richard Mahoney, Philip Musgrove, Ken Nelson, and Tomas Philipson. All errors are our own. Grant support: World Bank (DB, MKL), the Hopkins Population Center, NIH Grant SP30HD06268-25(DB), and the Bill and Melinda Gates Institute for Population and Reproductive Health (CWBK).

PY - 2001/11/12

Y1 - 2001/11/12

N2 - Economic models were used to describe the potential for an AIDS vaccine to prevent medical spending and lost productivity throughout the world. In terms of avoided medical spending, preventing 75% of the AIDS risk for 10 years in one adult male is estimated to be worth US$ 343 in western Europe, US$ 4.59 in south and SE Asia, and US$ 2.67 in sub-Saharan Africa. The expected medical savings from a 75% effective vaccine would exceed US$ 25.00 per person for over 700 million people. Although an AIDS vaccine would save more lives in poverty stricken areas, it would save more money in developed countries. The mismatch between the public health needs and market forces is highlighted by this model.

AB - Economic models were used to describe the potential for an AIDS vaccine to prevent medical spending and lost productivity throughout the world. In terms of avoided medical spending, preventing 75% of the AIDS risk for 10 years in one adult male is estimated to be worth US$ 343 in western Europe, US$ 4.59 in south and SE Asia, and US$ 2.67 in sub-Saharan Africa. The expected medical savings from a 75% effective vaccine would exceed US$ 25.00 per person for over 700 million people. Although an AIDS vaccine would save more lives in poverty stricken areas, it would save more money in developed countries. The mismatch between the public health needs and market forces is highlighted by this model.

KW - AIDS

KW - Costs

KW - Demand

KW - Economics

KW - Epidemiology

KW - HIV

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0035851351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035851351&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(01)00335-8

DO - 10.1016/S0264-410X(01)00335-8

M3 - Article

C2 - 11672918

AN - SCOPUS:0035851351

SN - 0264-410X

VL - 20

SP - 526

EP - 531

JO - Vaccine

JF - Vaccine

IS - 3-4

ER -

Modeling the economic benefits of an AIDS vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this